September 30, 2019
ESMO Sept 30 Successful launch of the MammaPrint and BluePrint NGS
Leonie JMJ Delahaye, Anke T Witteveen, Mireille HJ Snel1, Tyson Cavness, Bob Chan, Lorenza Mittempergher, Annuska M Glas
Successful launch of the MammaPrint and BluePrint NGS kit at decentralized sites
Centralized MammaPrint (MP) and BluePrint (BP) microarray-based genomic tests on FFPE RNA were successfully translated to a targeted RNA NGS kit that can be performed locally at decentralized sites. Since the launch of the CE-marked MP and BP NGS kit, more data has been generated on this platform with matching results on the established FDA-cleared microarray platform. Furthermore, decentralized sites worldwide have been onboarded and are certified to locally run the MP and BP NGS kit.